@misc{HasanHocher2017,
  author    = {Hasan, Ahmed Abdallah Abdalrahman Mohamed and Hocher, Berthold},
  title     = {Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy},
  series = {Journal of Molecular Endocrinology},
  volume    = {59},
  journal   = {Journal of Molecular Endocrinology},
  publisher = {Bioscientifica LTD},
  address   = {Bristol},
  issn      = {0952-5041},
  doi       = {10.1530/JME-17-0005},
  pages     = {R1 -- R10},
  year      = {2017},
  abstract  = {Diabetic nephropathy is one of the most frequent, devastating and costly complications of diabetes. The available therapeutic approaches are limited. Dipeptidyl peptidase type 4 (DPP-4) inhibitors represent a new class of glucose-lowering drugs that might also have reno-protective properties. DPP-4 exists in two forms: a plasma membranebound form and a soluble form, and can exert many biological actions mainly through its peptidase activity and interaction with extracellular matrix components. The kidneys have the highest DPP-4 expression level in mammalians. DPP-4 expression and urinary activity are up-regulated in diabetic nephropathy, highlighting its role as a potential target to manage diabetic nephropathy. Preclinical animal studies and some clinical data suggest that DPP-4 inhibitors decrease the progression of diabetic nephropathy in a blood pressure-and glucose-independent manner. Many studies reported that these reno-protective effects could be due to increased half-life of DPP-4 substrates such as glucagon-like peptide-1 (GLP-1) and stromal derived factor-1 alpha (SDF-1a). However, the underlying mechanisms are far from being completely understood and clearly need further investigations.},
  language  = {en}
}